Continuous Transdermal Nitroglycerin No Aid for Hot Flashes
Medically reviewed by Drugs.com.
By Lori Solomon HealthDay Reporter
FRIDAY, June 9, 2023 -- Uninterrupted transdermal nitroglycerin (NTG) therapy does not offer sustained benefit for hot flashes, according to a study published online June 5 in JAMA Internal Medicine.
Alison J. Huang, M.D., from the University of California in San Francisco, and colleagues randomly assigned 141 perimenopausal and postmenopausal women who experienced at least seven hot flashes per day to either uninterrupted daily use of transdermal NTG (participant-directed dose titration from 0.2 to 0.6 mg/hour) or identical placebo patches.
The researchers found that over five weeks, the estimated change in any hot flash frequency associated with NTG was −0.9 (95 percent confidence interval [CI], −2.1 to 0.3) episodes per day versus placebo, while change in moderate-to-severe hot flash frequency was −1.1 (95 percent CI, −2.2 to 0) episodes per day. Treatment with NTG did not significantly decrease the frequency of any hot flashes (−0.1 episodes per day; 95 percent CI, −1.2 to 0.4) or moderate-to-severe hot flashes (−0.5 episodes per day; 95 percent CI, −1.6 to 0.7) versus placebo at 12 weeks. Two-thirds of NTG users (67.1 percent) and 5.6 percent of placebo participants reported headache, which decreased to one participant in each group at 12 weeks.
"The findings of this trial do not support daily uninterrupted use of transdermal NTG as a nonhormonal treatment for menopause-associated vasomotor symptoms," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted June 2023
Read this next
More Physical Activity Tied to Higher Odds of Hot Flashes
FRIDAY, May 31, 2024 -- Increases in physical activity increase the odds of menopause-related hot flashes, according to a study published online May 28 in Menopause. Sarah...
ASCO: Conjugated Equine Estrogen May Increase Risk for Ovarian Cancer
TUESDAY, May 28, 2024 -- Conjugated equine estrogen (CEE) taken alone for menopause may increase the risk for developing and dying from ovarian cancer, according to a study...
Fezolinetant Safe, Effective for Moderate-to-Severe Menopause Hot Flashes
MONDAY, May 20, 2024 -- Fezolinetant is safe and effective for moderate-to-severe vasomotor symptoms (VMS), according to a study presented at the annual European Congress of...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.